

Symposium on Challenges in Breast Cancer Diagnostics

During September 2014, Agilent Technologies conducted an industry symposium at the largest European pathology congress, ECP. The symposium, entitled "Current Challenges in Breast Cancer Diagnostics: New Guidelines and Implementation in Clinical Practice", was attended by over 400 delegates, making this the most well-attended industry-sponsored symposium at this year's ECP.

The panel, made up of breast cancer pathology experts, gave the latest insights into the application of the ASCO/CAP guidelines as well as the practical management of testing in breast cancer.

The symposium was filmed and can be seen below.

[Share](#) [Tweet](#) [Share](#)

Chairman's Welcome to the Symposium

Dr. Kenneth Bloom's welcome to the symposium, "Current Challenges in Breast Cancer Diagnostics: New Guidelines and Implementation in Clinical Practice".



Implementation of ASCO/CAP Guidelines in Clinical Practice

Ian Ellis, Professor of Cancer Pathology, Nottingham University, talks about the UK's new imminent guidelines, the similarities and differences from the latest ASCO/CAP guidelines.

[View Video](#)



Navigating the Changing HER2 Testing Guidelines

Michael Press, Professor at USC Norris Comprehensive Cancer Center and a member of the ASCO/CAP committee, offers his personal perspectives on the ASCO/CAP guidelines and how data from his lab compares to the recent update to the ASCO/CAP guidelines on HER2 testing.

[View Video](#)



Everything You've Always Wanted to Know About Triple-Negative Breast Cancers

Dr. Reis-Filho Surgical Pathologist, Division of Experimental Pathology, Department of Pathology, Memorial Sloan Kettering Cancer Center presents hot topics within triple negative breast cancers, highlighting the current thinking and clinical studies leading to a greater understanding of the disease and how this will ultimately impact the potential of targeted therapy for patients in the future.



[View Video](#)

Implementing New Technologies and Future Perspectives

Professor Bloom, President/CEO Clariant Pathology Services, and chairman of this session, concludes the symposium by looking forward to an era where genome- based testing will become part of routine patient management, and how this may impact on the role of the pathologist.



[View Video](#)